Irodalom:
1. Vind I, Riis L, Jess T, et al: Increasing incidences of inflammatory bowel disease and decreasing surgery
rates in Copenhagen city and county, 2003-2005: a population-based study from the Danish Crohn
Colitis Database. Am J Gastroenterol 2006;101:1274-1282.
2. Bernstein CN, Wajda A, Svenson LW, et al: The epidemiology of inflammatory bowel disease in
Canada: a population-based study. Am J Gastroenterol 2006;101:1559-1568.
3. Lakatos L, Lakatos PL.: Is the incidence and prevalence of inflammatory bowel disease increasing in
Eastern Europe? Postgrad Med J 2006;82:332-337.
4. Lakatos L, Lakatos PL.: Is the incidence and prevalence of inflammatory bowel disease increasing in
Eastern Europe? Postgrad Med J 2006;82:457-465.
5. Wolters FL, Russel MG, Sijbrandij J, et al: Crohn’s disease: increased mortality 10 years after diagnosis
in a Europe-wide population based cohort. Gut 2006;55:510-518.
6. Jess T, Loftus EV Jr, Harmsen WS, et al: Survival and cause specific mortality in patients with inflammatory
bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006;55:
1248-1254.
7. Bernstein CN, Rawsthorne P, MCM Math, Blanchard JF.: A population-based case control study of
potential risk factors for IBD. Am J Gastroentzerol 2006;101:993-1002.
8. Amre DK, Lambrette P, Law L, et al: Investigating the hygiene hypothesis as a risk factor in pediatric onset
Crohn’s disease: a case-control study. Am J Gastroenterol 2006;101:1005-1011.
9. Lashner BA, Loftus EV Jr.: True or false? The hygiene hypothesis for Crohn’s disease. Am J
Gastroenterol 2006;101:1003-1004.
10. Vidal A, Gomet-Gil E, Sans M, et al: Life events and inflammatory bowel disease relapse: a prospective
study of patients enrolled in remission. Am J Gastroenterol 2006;101:775-781.
11. Nguyen GC, Torres EA, Regueiro M, et al: Inflammatory bowel disease characteristics among African
Americans, Hispanics, and non-hispanic whites: characterisation of a large North American cohort. Am
J Gastroenterol 2006;101:1012-1023.
12. Canavan C, Abrams KR, Hawthorne B, Mayberry JF.: Long-term prognosis in Crohn’s disease: an epi
demiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther
2007;25:59-65.
13. Takeuchi K, K, Smale S, Premchand P, et al: Prevalenmce and mechanism of nonsteroidal anti-inflammatory
drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol
2006;4:196-202.
14. Korzenik JR, Podolsky DK.: Selective use of selective nonsteroidal anti-inflammatory drugs in
inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:157-159.
15. Melmed GY, Ippoliti AF, Papadakis KA, et al: Patients with inflammatory bowel disease are at risk for
vaccine-preventable illness. Am J Gastroenterol 2006;101:1834-1840.
16. Tremaine WJ-Review article: Indeterminate colitis — definition, diagnosis and management. Aliment
Pharmacol Ther 2007;25:13-17.
17. Tang LY, Rawsthrone P, Bernstein CN.: Are perianal and luminal fistulas associated in Crohn’s disease?
A population-based study. Clin Gastroenterol Hepatol 2006;4:1130-1134.
18. Bar-Meir S. Review article: Capsule endoscopy — are all small intestinal lesions Crohn’s disease?
Aliment Pharmacol Ther 2006;24 (Suppl.3):19-21.
210 Gastro Update 2007
19. Bourreille A, Jarry M, D’Halluin PN, et al: Wireless capsule endoscopy versus ileocolonoscopy for the
diagnosis of postoperative recurrence of Crohn’s disease: a prospective study. Gut 2006;55:978-982.
20. Beaugerie L, Seksik P, Nion-Larmurier N, et al: Predictors of Crohn’s disease. Gastroenterology
2006;130:650-656.
21. Wolters FL, Russel MG, Sijbrandij J, et al: Phenotype at diagnosis predicts recurrence rates in Crohn’s
disease. Gut 2006;55:1124-1130.
22. Shen B, Fazion VW, Remzi FH, et al: Risk factors for diseases of ileal pouch-anal anastomosis after
restorative proftocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:81-89.
23. Riis L, Vind I, Politi P, et al: Does pregnancy change the disease course? A study in a European cohort
of patients with inflammatory bowel disease. Am J Gastroenterol 2006;101:1539-1545.
24. Canavan C, Abrams KR, Hawthorne B.: Long-term prognosis in Crohn’s disease: factors that affect
quality of life. Aliment Pharmacol Ther 2006;23:377-385.
25. Vermeire S, Van Assche G, Rutgeerts P. Review article: Altering the natural hystory of Crohn’s disease
— evidence for and against current therapies. Aliment Pharmacol Ther 2006;25:3-12.
26. D’Haens G, Hommes D, Engels L, et al: Once daily MMX mesalazine for the treatment of mild-to-moderate
ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24:1087-1097.
27. Ho G-T, Chiam P, Drummond H, et al: The efficacy of corticosteroid therapy in inflammatory bowel
disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319-330.
28. *Ardizzone S, Maconi G, Russo A, et al: Randomised controlled trial of azathioprine and 5-aminosalicylic
acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.
29. Moskovitz DN, Van Assche G, Maenhout B, et al: Incidence of colectomy during long-term follow-up
after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:
760-765.
30. Yamamoto T, Nakahigashi M, Umegae S, et al: Impact of long-term enteral nutrition on clinical and
endoscopic recurrence after resection for Crohn’s disease: a prospective, non randomized, parallel, controlled
study. Aliment Pharmacol Ther 2007;25:67-72.
31. Takagi S, Utsinomiya K, Kuriyama S, et al: Effectiveness of an “half elemental diet” as a maintenance
therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther 2006;24:1333-1340.
32. Johnson T, Macdonald S, Hill SM, et al: Treatment of active Crohn’s disease in children using partial
enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006;55:356-361.
33. Borelli O, Cordischi L, Cirulli M, et al: Polymeric diet alone versus corticosteroid sin the treatment of
active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol
2006;4:744-753.
34. Gisbert JP, Nino P, Rodrigo L, et al: Thiopurin methyltransferase (TPMT) activity and adverse effects
of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J
Gastroenterol 2006.101:2769-2776.
35. Schmidt C, Wittig BM, Moser C, et al: Cyclophosphamide pulse therapy follwed by azathioprine or
methotrexate induces long-term remission in patients with steroid-refractory Crohn’s disease. Aliment
Pharmacol Ther 2006;24:343-350.
36. Baumgart DC, Pintoffl JP, Sturm A, et al: Tacrolimus is safe and effective in patients with severe
steroid-refractory or steroid-dependent inflammatory bowel disease — a long term follow up. Am J
Gastroenterol 2006;101:1048-1056.
37. Langagergaard V, Pedersen L, Gislum M, et al: Birth outcome in women treated with azathioprine or
mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol ther
2007;25:73-81.
38. Kevans D, Keegan D, Mulhacy HE, et al: Infliximab therapy in Crohn’s disease: a pragmatic approach?
Aliment Pharmacol Ther 2006;24:351-359.
A vastagbél 211
39. Lichtenstein G, Olson A, Travers S, et al: Factors associated with the development of intestinal strictures
or obstructions in patients with Crohn’s disease. Am J Gastroenterol 2006;101:1030-1038.
40. Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis.
Aliment Pharmacol Ther 2006;25:1937.
41. Lichtenstein GR, Feagan BG, Cohen RD, et al: Serious in fections and mortality in association with
therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630.
42. Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn’s disease. Aliment
Pharmacol Ther 2006;24:1283-1293.
43. Brooklyn TN, Dunnill MGS, Shetty A, et al: Infliximab for the treatment of pyoderma gangraenosum: a
randomised, double blind, placebo controlled trial. Gut 2006;55:505-509.
44. Biancone L, Orlando A, Kohn A, et al: Infliximab and newly diagnosed neoplasia in Crohn’s disease:
a multicentre matched pair study. Gut 2006:228-233.
45. Hanauer SB, Sandborn WJ, Rutgeerts P, et al: Human anti-tumor necrosis factor monoclonal antobody
(adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333.
46. Hommes DW, Mikhajlova TL, Stoinov A, et al: Fontolizumab, a humanised anti-interferon-γ antibody,
demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut
2006;55:1131-1137.
47. Miner PB Jr, Wedel MK, Xia S, Baker BF.: Safety and efficacy of two dose formulations of alicaforsen
enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis:
a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006;1403-1413.
48. Creed TJ, Probert CSJ, Norman NM, et al: Basilixoóimab fr the treatment of steroid-resistant ulcerative
colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-1442.
49. Prantera C, Lochs H, Campieri M, et al: Antibiotic treatment of Crohn’s diesease: results of a multicentre,
double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;
23:1117-1125.
50. Zocco MA, Zileri Dal Velme L, Cremonini F, et al: Efficacy of Lactobacillus GG in maintaining remission
of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-1574.
51. Marteau P, Lémann M, Seksik P, et al: Ineffevctiveness of Lactobacillus Johnsonii LA1 for profilaxis
of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled
GETAID trial. Gut 2006;55:842-847.
52. Marteau P.: Probiotics, prebiotics and symbiotics: ecological treatment for inflammatory bowel disease?
Gut 2006;55:1692-1693.
53. Lindsay JO, Whelan K, Stagg AJ, et al: Clinical, microbiological, and immunological effects of
ructoolygosacharide in patients with Crohn’s disease. Gut 2006;55:348-355.
54. Zezos P, Papaioannou G, Nikolaidis N, et al: Low-molecular-weight heparin (enoxaparin) as adjuvant
therapy in the treatment of active ulcerative colitis: a randomized, controlled, comaprative study.
Aliment Pharmacol Ther 2006;23:1443-1453.
55. Gassull MA. Review article: The intestinal lumen as a therapeutic target in inflammatory bowel disease.
Aliment Pharmacol Ther 2006;24 (Suppl.3):90-95.
56. Margalit M, Israeli E, Shibolet O, et al: Double blind clinical trial for treatment of Crohn’s disease by
oral administration of AlequelTM, a mixture of autologous colon-extracted proteins: a patient-tailored
approach. Am J Gastroenterol 2006;101:561-568.
57. Gutierrez A, Lee H, Sands BE.: Outcome of surgical versus percutaneous drainage of abdominal and
pelvic abscess in Crohn’s disease. Am J Gastroenterol 2006;101:2283-2289.
58. Travis S. Review article: saving the colon in severe colitis ? the case for medical therapy. Aliment
Pharmacol Ther 2006;24 (Suppl.3):68-73.
59. Öresland T. Review article: colon saving medical therapy vs. colectomy in ulcerative colitis. the case
212 Gastro Update 2007
for colectomy. Aliment Pharmacol Ther 2006;24 (Suppl.3):74-79.
60. Waljee A, Waljee J, Morris AM, Higgins PDR.: Threefold increased risk of infertility: a meta-analysis
of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006;55:1575-1580.
61. Kane S, Dixon L.: Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol
Ther 2006;24:1099-1103.
62. Lopez-Sanromán A, Bermejo F.: Review article: how to control and improve adherence to therapy in
inflammatory bowel disease. Aliment Pharmacol Ther 2006;24 (Suppl.3):45-49.
63. Stange EF. Review article: The effect of aminosalicylates and immunomodulation on cancer risk in
inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:64-67.
64. Eaden JA, Abrams K, Mayberry JF.: The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut 2001;48:526-535.
65. Jensen AB, Larsen M, Gislum M, et al: Survival after colorectal cancer in patients with ulcerative colitis:
a nationwide population-based Danish study. Am J Gastroenterol 2006;101:1283-1287.
66. Lakatos L, Mester G, Erdélyi Zs, et al: Risk Factors for ulcerative colitis-associated colorectal cancer
in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm
Bowel Dis 2006;12:1-12.
67. Velayos FS, Loftus EV Jr, Jess T, et al: Predictive and protective factors associated with colorectal cancer
in ulcerative colitis: a case-control study. Gastroenterology 2006;130:1941-1949.
68. Delaunoit T, Limburg PJ, Goldberg RM, et al: Colorectal cancer prognosis among patients with inflammatory
bowel disease. Clin Gastroenterol Hepatol 2006;4:335-342.
69. Rutter MD, Saunders BP, Wilkinson KH, et al: Thirty-year analysis of colonscopic surveillance program
for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-1038.
70. Vieth M, Behrens H, Stolte M.: Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate
treatment. Gut 2006;55:1151-1155.
71. Jess J, Loftus EV Jr, Velayos F, et al: Risk of intestinal cancer in inflammatory bowel disease: a
population-based study from Olmsted county, Minnesota. Gastroenterology 2006;130:1039-1046.
72. Limburg PJ, Vierkant RA, Fredericksen ZS, et al: Clinically confirmed type 2 diabetes mellitus and colorectal
cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006;101:1872-1879.
73. Van Guelpen B, Hultdin J, Johansson J, et al: Low folate levels may protect against colorectal cancer.
Gut 2006;55:1461-1466.
74. Shack LG, Wood HE, Kang JY, et al: Small intestinal cancer in England, Wales and Scotland: time
trends in incidence, mortality and survival. Aliment Pharmacol Ther 2006;23:1297-1306.
75. Das A, Chak A, Cooper GS.: Temporal trend in relative risk of second primary colorectal cancer. Am
J Gastroenterol 2006;101:1342-1347.
76. Ross AS, Waxman I.: Flat and depressed neoplasms of the colon in western populations. Am J
Gastroenterol 2006;101:192-180.
77. Goto H, Oda Y, Murakami Y, et al: Proportion of de novo cancers among colorectal cancers in Japan.
Gastroenterology 2006;131:40-46.
78. Chow E, Lipton L, D’Sousa R, et al: Hyperplastic polyposis syndrome: phenotypic presentations and
the role of MBD4 and MYH. Gastroenterology 2006;131:30-39.
79. Sung J.: Does fecal occult blood test have a place for colorectal cancer screening in China in 2006? Am
J Gastroenterol 2006;101:213-215.
80. Steele RJC.: Fecal occult blood test screening int he United Kingdom. Am J Gastroenterol 2006;
101:216-218.
81. Bond JH.: The place of fecal occult blood test in colorectal cancer screening in 2006: The U.S. per
spective. Am J Gastroenterol 2006;101:219-221.
A vastagbél 213
82. Strul H, Kariv R, Leshno M, et al: The prevalence rate and anatomic location of colorectal adenoma
and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. Am J Gastroenterol
2006;101:255-262.
83. Regula J, Rupinski M, Kraszewska E, et al: Colonoscopy in colorectal-cancer screening for detection
of advanced neoplasia. N Engl J Med 2006;355:1863-1872
84. Brenner H, Chang-Claude J, Seiler CM, et al: Does a negative screening colonoscopy ever need to be
repeated? Gut 2006;55:1145-1150.
85. Cottet V, Pariente A, Nalet B, et al: Low compliance with colonoscopic screening in first-degree relatives
of patients with large adenomas. Aliment Pharmacol Ther 2006;24:101-109.
86. Lin OS, Kozarek RA, Schembre DW, et al: Screening colonoscopy in very elderly patients. JAMA
2006;295:2357-2365
87. Gross CP, McAvay GJ, Krumholz HM, et al: The effect of age and chronic illness of life expectancy
after a diagnosis of colorectal cancer: implications for screening. Ann Int Med 2006;145:646-653.
88. Singh H, Turner D, Xue L, et al: Risk of developing colorectal cancer following a negative colonoscopy
examination. JAMA 2006;295:2366-2373.
89. Rex DK, Kahi CJ, Levin B, et al: Guidelines for colonoscopy surveillance after cancer resection: a consensus
update by the American Cancer Society and US Multy-Society Task Force on colorectal cancer. CA
Cancer J Clin 2006;56:160-167.
90. Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemoprevention of
colorectal adenomas. Gastroenterology 2006;131:1674-1682.
91. Bertagnolli MM, Eagle CJ, Cauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas
N Engl J Meg. 2006;555:873-884.
92. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N
Engl J Med 2006;355:885-895.
93. Psaty BM, Potter JD.: Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med
2006;355:950-952.
94. Arber N, Kuwada S, Leshno M, et al: Sporadic adenomatous polyp regression with exisulind is effective
but toxic: a randomised, double blond, placebo controlled, dose-response study. Gut 2006;55:367-373.
95. Bjelakovic G, Nagorni A, Nikolova D, et al: Meta-analysis: antioxidant supplements for primary and
secondary prevention of colorectal adenoma. Aliment Pharmacol Ther 2006;24:281-291.
96. Drosmann DA.: The functional gastrointestinal disorders and the Rome III process. Gastroenterology
2006;130:1377-1380.
97. Longstreth GF, Thompson WG, Chey WD, et al: Functional bowel disorders. Gastroenterology
2006;130:1480-1491.
98. Whitehead WE, Palsson OS, Feld AD, et al: Utility of red flag symptom exclusion in the diagnosis of
irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:137-146.
99. Halvorson HA, Schlett CD, Riddle MS.: Postinfectious irritable bowel syndrome — a meta-analysis.
Am J Gastroenterol 2006;101:1894-1899.
100. Jones R, Latinovic R, Charlton J, Gulliford M.: Physical and psychological co-morbidity in irritable
bowel syndrome: a matched cohort study using General Practice Research Database. Aliment
Pharmacol Ther 2006;24:879-886.
101. Chang L, Chey WD, Harris L, et al: Incidence of ischaemic colitis and serious complications of constipation
among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Am J Gastroenterol 2006;101:1069-1079.
102. Tack J, Broekaert D, Fischler B, et al: A controlled crossover study of the selective serotonin reuptake
inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103.
103. Sharara AI, Aoun E, Abdul-Baki H, et al: A randomized double-blind placebo-controlled trial of rifaximin
214 Gastro Update 2007
in patients abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-333.
104. Pimentel M, Park S, Mirocha J, et al: The effect of a nonabsorbed oral antibiotic (rifaximin) on the
symptoms of the irritable bowel syndrome. Ann Int Med 2006;145:557-563.
105. Drossmann DA.: Treatment for bacterial overgroth in the irritable bowel syndrome. Ann Int Med
2006;145:626-628.
106. Dunlop SP, Hebden J, Campbell E, et al: Abnormal intestinal permeability in subgroups of dirrhea-pre
dominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-1294.
107. Leung WK, Wu JCY, Liang SM, et al: Treament of diarrhea-predominant irritable bowel syndrome with
traditional chinese herbal medicine: a randomized-controlled trial. Am J Gastroenterol 2006;101:1574-1580.
108. Schneider A, Enck P, Streitberger K, et al: Acupuncture treatment in irritable bowel syndrome. Gut
2006;55:649-654.
109. Yearsley KA, Gilby AV, Ramadas AV, et al: Proton pump inhibitor therapy is a risk factor for
Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613-619.
110. Laine L, Smith R, Min K, et al. Systemic review: The lower gastrointestinal adverse effects of non-steroidal
anti-inflammatory drugs. Aliment Pharmacol Ther 2006;24:751-767
